These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7750983)

  • 21. Chemotactic factor inactivation by stimulated human neutrophils mediated by myeloperoxidase-catalyzed methionine oxidation.
    Clark RA; Szot S
    J Immunol; 1982 Apr; 128(4):1507-13. PubMed ID: 6278020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The terminal membrane C5b-9 complex of human complement. Evidence for the existence of multiple protease-resistant polypeptides that form the trans-membrane complement channel.
    Bhakdi S; Tranum-Jensen J; Klump O
    J Immunol; 1980 May; 124(5):2451-7. PubMed ID: 6154104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement lysis: evidence for an amphiphilic nature of the terminal membrane C5b-9 complex of human complement.
    Bhakdi S; Bjerrum OJ; Bhakdi-Lehnen B; Tranum-Jensen J
    J Immunol; 1978 Dec; 121(6):2526-32. PubMed ID: 569173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deviated lysis: transfer of complement lytic activity to unsensitized cells. IV. Parital isolation of the activity.
    Hänsch G; Rother U; Rother K
    Z Immunitatsforsch Immunobiol; 1977 Apr; 153(1):48-59. PubMed ID: 868206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The C5b-9 complex: subunit composition of the classical and alternative pathway-generated complex.
    Podack ER; Kolb WP; Muller-Eberhard HJ
    J Immunol; 1976 May; 116(5):1431-4. PubMed ID: 1270802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement-induced ultrastructural membrane lesions: requirement for terminal components.
    Packman CH; Rosenfeld SI; Weed RI; Leddy JP
    J Immunol; 1976 Nov; 117(5 Pt.2):1883-9. PubMed ID: 993584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation.
    Muhlfelder TW; Niemetz J; Kreutzer D; Beebe D; Ward PA; Rosenfeld SI
    J Clin Invest; 1979 Jan; 63(1):147-50. PubMed ID: 762243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement component C7 is a plasminogen-binding protein.
    Reinartz J; Hänsch GM; Kramer MD
    J Immunol; 1995 Jan; 154(2):844-50. PubMed ID: 7814888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Freeze-thaw activation of the complement attack phase: II. Comparison of convertase generated C--56 with C--56 generated by freezing and thawing.
    Dessauer A; Rother U; Rother K
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():83-8. PubMed ID: 6444196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity.
    Yamamoto KI
    J Immunol; 1977 Oct; 119(4):1482-5. PubMed ID: 894048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding of iron to the 5th component of human complement directs oxygen radical-mediated conversion to specific sites and causes nonenzymic activation.
    Vogi W; Nolte R; Brunahl D
    Complement Inflamm; 1991; 8(5-6):313-9. PubMed ID: 1666352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement-independent activation of the fifth component (C5) of human complement: limited trypsin digestion resulting in the expression of biological activity.
    Wetsel RA; Kolb WP
    J Immunol; 1982 May; 128(5):2209-16. PubMed ID: 7061860
    [No Abstract]   [Full Text] [Related]  

  • 33. Biosynthesis of the third and fifth complement components by isolated human lung cells.
    Rothman BL; Merrow M; Bamba M; Kennedy T; Kreutzer DL
    Am Rev Respir Dis; 1989 Jan; 139(1):212-20. PubMed ID: 2912341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunoenzyme determination of the C5b-9 complex of the complement system].
    Rus H; Niculescu F; Cristea A; Vlaicu R
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1986; 31(1):35-40. PubMed ID: 3738363
    [No Abstract]   [Full Text] [Related]  

  • 35. Cleavage of the fifth component of human complement and release of a split product with C5a-like activity by crystalline silica through free radical generation and kallikrein activation.
    Governa M; Fenoglio I; Amati M; Valentino M; Bolognini L; Coloccini S; Volpe AR; Carmignani M; Fubini B
    Toxicol Appl Pharmacol; 2002 Mar; 179(3):129-36. PubMed ID: 11906242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement components C5 and C7: recombinant factor I modules of C7 bind to the C345C domain of C5.
    Thai CT; Ogata RT
    J Immunol; 2004 Oct; 173(7):4547-52. PubMed ID: 15383587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs.
    Rollins SA; Matis LA; Springhorn JP; Setter E; Wolff DW
    Transplantation; 1995 Dec; 60(11):1284-92. PubMed ID: 8525523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taurine chloramine is more selective than hypochlorous acid at targeting critical cysteines and inactivating creatine kinase and glyceraldehyde-3-phosphate dehydrogenase.
    Peskin AV; Winterbourn CC
    Free Radic Biol Med; 2006 Jan; 40(1):45-53. PubMed ID: 16337878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloperoxidase-mediated oxidation of methionine.
    Tsan MF
    J Cell Physiol; 1982 Apr; 111(1):49-54. PubMed ID: 6282905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C5-dependent enhancement of rosette formation and phagocytosis by human polymorphonuclear leukocytes.
    Segerling M; Opferkuch W
    Monogr Allergy; 1977; 12():101-4. PubMed ID: 917012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.